Is sirolimus-induced hyperlipidaemia in liver transplant recipients dose-dependent?
All six patients showed either resolution or improvement in lipid levels with discontinuation of sirolimus.
Clinical evaluation of CX-4945 in humans as a single agent in solid tumors and multiple myeloma has established its promising pharmacokinetic, pharmacodynamic, and safety profiles. Beyond regression of tumor mass, CX-4945 may be advanced as a new therapy for cancer metastasis and EMT-related disorders.